Gujarat Magazine

Age-related Macular Degeneration Pipeline Insights, 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Competitive Landscape, Companies | Novartis, Alexion Pharmaceuticals, AstraZeneca

 Breaking News
  • No posts were found

Age-related Macular Degeneration Pipeline Insights, 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Competitive Landscape, Companies | Novartis, Alexion Pharmaceuticals, AstraZeneca

June 03
10:10 2024
Age-related Macular Degeneration Pipeline Insights, 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Competitive Landscape, Companies | Novartis, Alexion Pharmaceuticals, AstraZeneca
Age-related Macular Degeneration Pipeline Insights 2024
As per DelveInsight, the Age-related Macular Degeneration (AMD) therapeutics market is anticipated to evolve immensely in the coming years owing to the expected launch of therapies and the increasing prevalence of AMD. Companies across the globe are diligently working toward the development of novel treatment therapies, with a considerable amount of success over the years.

At present, pharmaceutical companies such as Apellis Pharmaceuticals (Pegcetacoplan), Iveric bio (Zimura), Genentech (Roche; RO7171009; RG6147), Ionis Pharmaceuticals/ Roche (IONIS-FB-LRx), Allegro Ophthalmics (Luminate), NGM Biopharmaceuticals (NGM621), Stealth BioTherapeutics (Elamipretide), Regenerative Patch Technologies (CPCB-RPE1), CellCure Neurosciences/Lineage Cell Therapeutics/ Roche (OpRegen), Gyroscope Therapeutics (GT005), and others, are working on developing a novel approach to treat Age-related Macular Degeneration (AMD).

The emerging therapies are based on different types of mechanisms of action, including C3 inhibitors, C5 inhibitors, Integrin Inhibitors, Anti-C1q antibody, Anti-C3 antibody, Factor D inhibitors, HtrA1, ASO Complement Factor B, and others.

Age-related Macular Degeneration (AMD) Pipeline Insight, 2024” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Age-related Macular Degeneration Market. 

The Age-related Macular Degeneration Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Age-related Macular Degeneration (AMD) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Age-related Macular Degeneration and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Age-related Macular Degeneration market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the Age-related Macular Degeneration Therapeutic Segment @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight

The Leading Companies in the Age-related Macular Degeneration (AMD) Therapeutics Market Include:

Alexion Pharmaceuticals, Alkahest Inc, Alkeus Pharmaceuticals, Allegro Ophthalmics, Annexon Biosciences, Apellis Pharmaceuticals, AstraZeneca, CellCure Neurosciences, Clearside Biomedical, Evergreen Therapeutics, Gemini Therapeutics, Graybug Vision, Gyroscope Therapeutics and Novartis, Ionis Pharmaceuticals, Iveric Bio, Kodiak Sciences Inc., Luxa Biotechnology, NGM Biopharmaceuticals, Novartis, Opthea Limited, Outlook Therapeutics, Inc., PanOptica, Inc., Regenerative Patch Technologies, Regeneron Pharmaceuticals, REGENXBIO, Ribomic USA Inc, Roche, Stealth BioTherapeutics, Unity Biotechnology, Inc, and many more.

Age-related Macular Degeneration Marketed and Emerging Drugs Covered in the Report Include:

  • Beovu (brolucizumab): Novartis

  • Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca

  • EG-301: Evergreen Therapeutics

  • Eylea (aflibercept): Regeneron Pharmaceuticals

  • KSI-301: Kodiak Sciences Inc.

  • Lucentis (ranibizumab): Roche

  • OPT-302: Opthea Limited

  • RGX-314: Regenxbio

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight 

Table of Contents

1. Report Introduction

2. Executive Summary

3. Age-related Macular Degeneration Current Treatment Patterns

4. Age-related Macular Degeneration – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Age-related Macular Degeneration Late Stage Products (Phase-III)

7. Age-related Macular Degeneration Mid-Stage Products (Phase-II)

8. Age-related Macular Degeneration Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Age-related Macular Degeneration Discontinued Products

13. Age-related Macular Degeneration Product Profiles

14. Key Companies in the Age-related Macular Degeneration Market

15. Key Products in the Age-related Macular Degeneration Therapeutics Segment

16. Dormant and Discontinued Products

17. Age-related Macular Degeneration Unmet Needs

18. Age-related Macular Degeneration Future Perspectives

19. Age-related Macular Degeneration Analyst Review  

20. Appendix

21. Report Methodology

Download Sample PDF to Explore the Key Offerings of the Report: https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Recent Posts

ESL Tutoring Services Expands English Tutoring Services in Sydney and Melbourne

Read Full Article

Categories